Daily Derm Times: June 20, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Q&A Part 1: Reviewing the Significance of Lebrikizumab for Patients With Skin of Color, With Anabela Cardoso, MD

Anabela Cardoso, MD, shares data from the phase 3b ADmirable trial—the first study to evaluate the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

FDA Approves Dupilumab, First and Only Targeted Medicine for Bullous Pemphigoid

Dupilumab gains FDA approval as the first targeted therapy for bullous pemphigoid, offering hope for effective treatment and improved patient outcomes.

Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 3

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the final day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Nail Trends That Challenge Clinical Diagnosis

Trendy manicures like Russian nails and 3D art may complicate diagnosis or cause damage, making them important for dermatologists to recognize.

HS Uncovered: Global Survey Highlights Patient Perspectives and Psychosocial Impact

A global survey reveals the significant psychosocial and financial burdens of hidradenitis suppurativa, highlighting the need for improved patient care and treatment options.